Needham raised the firm’s price target on Centessa (CNTA) to $38 from $35 and keeps a Buy rating on the shares. The stock’s momentum is likely to continue in 2026 due to additional data from the ongoing dose escalation cohorts in ORX-750’s ongoing Phase 2a study, the analyst tells investors in a research note. Needham believes Centessa is likely one of the most attractive biotechnology acquisition targets in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA: